Compare
BillionToOne, Inc. vs Castle Biosciences Inc vs CareDx, Inc. vs Veracyte, Inc.
| Latest fiscal year | BillionToOne, Inc. BLLN | Castle Biosciences Inc CSTL | CareDx, Inc. CDNA | Veracyte, Inc. VCYT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $305.11M | $344.23M | $379.81M | $517.14M |
| Revenue growth (YoY) | +100.0% | +3.7% | +13.8% | +16.0% |
| Gross margin | 68.3% | 79.4% (computed) | n/a | 70.1% |
| Operating margin | 5.3% | -12.4% | -8.1% | 11.2% |
| Net margin | 2.4% | -7.0% | -5.6% | 12.8% |
| Net income | $7.45M | -$24.16M | -$21.35M | $66.35M |
| EPS (Diluted) | $0.14 | -$0.83 | -$0.40 | $0.82 |
| Operating cash flow | $24.59M | $64.35M | $42.03M | $136.31M |
| Free cash flow | $15.71M | $28.33M | n/a | $126.63M |
| Cash & equivalents | $495.98M | $116.73M | $65.43M | $362.58M |
| Total assets | $632.65M | $578.56M | $413.23M | $1.41B |
| Total liabilities | $152.55M | $107.68M | $110.13M | $96.44M |
| Shareholders' equity | $480.11M | $470.87M | $303.10M | $1.31B |
| Return on year-end equity | 1.6% | -5.1% | -7.0% | 5.1% |
| Shares outstanding | n/a | 29.69M | 50.92M | 79.36M |
Revenue, most recent five fiscal years
| Fiscal year | BillionToOne, Inc. | Castle Biosciences Inc | CareDx, Inc. | Veracyte, Inc. |
|---|---|---|---|---|
| Latest | $305.11M Ended 2025-12-31 | $344.23M Ended 2025-12-31 | $379.81M Ended 2025-12-31 | $517.14M Ended 2025-12-31 |
| 1 year earlier | $152.58M Ended 2024-12-31 | $332.07M Ended 2024-12-31 | $333.79M Ended 2024-12-31 | $445.76M Ended 2024-12-31 |
| 2 years earlier | $71.73M Ended 2023-12-31 | $219.79M Ended 2023-12-31 | $280.32M Ended 2023-12-31 | $361.05M Ended 2023-12-31 |
| 3 years earlier | n/a | $137.04M Ended 2022-12-31 | $321.79M Ended 2022-12-31 | $296.54M Ended 2022-12-31 |
| 4 years earlier | n/a | $94.08M Ended 2021-12-31 | $296.40M Ended 2021-12-31 | $219.51M Ended 2021-12-31 |